GO:0005024 transforming growth factor beta receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005024 transforming growth factor beta receptor activity describes the molecular function of receptors that bind TGF-beta and transmit signals by phosphorylating protein serine and threonine residues.
• The core receptors are TGFBR1 (ALK5) and TGFBR2, which form a ligand-induced heteromeric complex; TGFBR3 (betaglycan) modulates ligand presentation.
• TGF-beta receptor signaling controls cell proliferation, differentiation, migration, extracellular matrix production, and immune regulation, and its dysregulation is linked to fibrosis, cancer, and kidney disease.
• Small-molecule inhibitors such as SB-431542 and TK-850 selectively block TGF-beta receptor kinase activity and reduce fibrosis in preclinical models.
• TGF-beta receptor activity intersects with p38 MAPK, PI3K/AKT, and interleukin-1 receptor-like 1 signaling, shaping context-dependent outcomes.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of TGF-beta receptor function in disease and development.
Description
Transforming growth factor beta (TGF-beta) receptor activity (GO:0005024) is a molecular function that combines ligand binding with transmembrane signal transduction through protein serine/threonine kinase activity. This activity is essential for converting extracellular TGF-beta signals into intracellular phosphorylation events that regulate gene expression and cell behavior. Researchers study this function because it governs fundamental processes such as cell growth, differentiation, apoptosis, and extracellular matrix remodeling, and because its perturbation contributes to fibrosis, cancer, and immune disorders. The receptors that carry this activity are serine/threonine kinases, distinguishing them from many growth factor receptors that phosphorylate tyrosine residues. Understanding GO:0005024 therefore requires integrating ligand-receptor biochemistry, kinase mechanism, and downstream pathway crosstalk.
transforming growth factor beta receptor activity At A Glance
| GO ID | GO:0005024 |
|---|---|
| GO term | transforming growth factor beta receptor activity |
| Ontology | molecular_function |
| Synonym | TGFbeta-activated receptor activity; TGFbetaR; TGF-beta receptor activity; TGFbeta receptor activity; transforming growth factor beta-activated receptor activity |
| Major function | Binds TGF-beta and transmits signal by ATP-dependent phosphorylation of protein serine and threonine residues |
| Receptor type | Serine/threonine protein kinase receptor |
| Core receptors | TGFBR1 (ALK5), TGFBR2, and accessory TGFBR3 |
| Pathway context | TGF-beta signaling with crosstalk to p38 MAPK, PI3K/AKT, and IL1RL1 pathways |
| Disease relevance | Fibrosis, cancer, kidney disease, wound healing, and immune regulation |
What Is GO:0005024?
GO:0005024 transforming growth factor beta receptor activity is defined as the function of combining with a TGF-beta ligand and transmitting the signal across the membrane to initiate a change in cell activity by catalyzing the phosphorylation of protein serine and threonine residues using ATP. In practical terms, it is a ligand-activated serine/threonine kinase activity that couples extracellular TGF-beta binding to intracellular phosphorylation events.
Why Is transforming growth factor beta receptor activity Important in Cell Biology?
GO:0005024 is important because it defines the initiating biochemical step of TGF-beta signaling, a pathway that controls proliferation, differentiation, migration, extracellular matrix production, and immune homeostasis. Dysregulated TGF-beta receptor activity is a driver or modifier of fibrosis in kidney, skin, and other organs, and it influences tumor progression and metastasis through crosstalk with PI3K/AKT and MAPK pathways. Because the activity is druggable and genetically tractable, it is a central target for mechanistic studies and therapeutic development.
• Controls cell proliferation, differentiation, and apoptosis through serine/threonine phosphorylation of downstream effectors.
• Drives extracellular matrix deposition and myofibroblast differentiation in wound healing and fibrosis.
• Modulates immune responses and inflammation, partly through crosstalk with IL1RL1 signaling.
• Is frequently altered in cancer, where it can act as a tumor suppressor or promoter depending on context.
• Is implicated in kidney diseases, including membranous nephropathy associated with TGFBR3.
• Provides a validated drug target; inhibitors such as SB-431542 and TK-850 block receptor kinase activity.
• Integrates with p38 MAPK and PI3K/AKT pathways to shape context-specific outcomes.
• Enables precise genetic dissection using CRISPR knockout, point mutation, knock-in, and overexpression models.
Molecular Mechanism of transforming growth factor beta receptor activity
Ligand binding and receptor complex assembly
In simple terms: TGF-beta binds to its receptors on the cell surface and brings them together.
TGF-beta ligands bind to TGFBR2, a constitutively active serine/threonine kinase, which then recruits and phosphorylates TGFBR1 (ALK5) to form an active heteromeric complex. TGFBR3 (betaglycan) can present ligand to the signaling receptors and modulate their activity. This assembly step is the first committed event in GO:0005024 function.
Kinase activation and substrate phosphorylation
In simple terms: The receptor turns on and adds phosphate groups to target proteins.
Activated TGFBR1 phosphorylates SMAD2 and SMAD3 on serine and threonine residues, which is the catalytic hallmark of GO:0005024. The receptor uses ATP as the phosphate donor, consistent with the definition of protein serine/threonine kinase activity. This phosphorylation event initiates downstream transcriptional responses.
Non-SMAD signaling crosstalk
In simple terms: The receptor also talks to other signaling pathways beyond SMADs.
TGF-beta receptor activity can activate p38 MAPK and PI3K/AKT pathways, which contribute to myofibroblast differentiation and cancer progression. Crosstalk with interleukin-1 receptor-like 1 signaling further modulates fibrotic responses. These non-SMAD branches expand the biological impact of GO:0005024.
Regulation by inhibitors and accessory proteins
In simple terms: Other molecules can block or tune the receptor's activity.
Small-molecule inhibitors such as SB-431542 selectively inhibit ALK4, ALK5, and ALK7, directly blocking TGF-beta receptor kinase activity. TK-850, a dual inhibitor of TGFBR1 and MAP4K4, reduces renal fibrosis in vivo. Accessory proteins like TGFBR3 can also modulate ligand availability and receptor function.
Key Genes Involved in GO:0005024 transforming growth factor beta receptor activity
The following genes encode the receptors, ligands, and signaling components most directly associated with GO:0005024 transforming growth factor beta receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFBR1 | Type I receptor (ALK5) with serine/threonine kinase activity | Primary catalytic subunit; target of SB-431542 and TK-850 |
| TGFBR2 | Type II receptor that binds ligand and activates TGFBR1 | Essential for ligand-induced complex formation |
| TGFBR3 | Betaglycan; accessory receptor that modulates ligand presentation | Associated with membranous nephropathy |
| SMAD2 | Receptor-regulated SMAD phosphorylated by TGFBR1 | Key downstream effector of receptor activity |
| SMAD3 | Receptor-regulated SMAD phosphorylated by TGFBR1 | Mediates transcriptional responses |
| SMAD4 | Common SMAD that partners with SMAD2/3 | Central to canonical TGF-beta signaling |
| MAPK14 | p38 MAPK involved in non-SMAD signaling | Drives myofibroblast differentiation |
| PIK3CA | PI3K catalytic subunit in AKT pathway | Crosstalk with TGF-beta receptor in cancer |
| AKT1 | Serine/threonine kinase downstream of PI3K | Mediates survival and proliferation signals |
| IL1RL1 | Interleukin-1 receptor-like 1 | Crosstalk promotes renal fibrosis |
| MAP4K4 | Mitogen-activated protein kinase kinase kinase kinase 4 | Target of TK-850 in fibrosis models |
| ALK4 | Activin receptor-like kinase 4 | Inhibited by SB-431542 |
| ALK7 | Activin receptor-like kinase 7 | Inhibited by SB-431542 |
| COL1A1 | Type I collagen | Readout of TGF-beta-driven fibrosis |
| ACTA2 | Alpha smooth muscle actin | Marker of myofibroblast differentiation |
| FN1 | Fibronectin | Extracellular matrix component induced by TGF-beta |
| SERPINE1 | PAI-1 | Transcriptional target of TGF-beta signaling |
| JUNB | AP-1 transcription factor | Immediate early target of TGF-beta |
How Is transforming growth factor beta receptor activity Regulated?
TGF-beta receptor activity is regulated at multiple levels. Ligand availability and accessory proteins such as TGFBR3 modulate receptor engagement. Small-molecule inhibitors like SB-431542 and TK-850 directly block the kinase activity of TGFBR1 and related ALK receptors. Downstream, p38 MAPK and PI3K/AKT pathways provide feedback and crosstalk that shape the duration and intensity of signaling. Interleukin-1 receptor-like 1 signaling can also intersect with TGF-beta receptor pathways to promote fibrosis.
transforming growth factor beta receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR1 | Renal fibrosis | Knockout or point-mutation in renal fibroblasts; TK-850 treatment |
| TGFBR2 | Fibrosis and cancer | Conditional knockout in fibroblasts or epithelial cells |
| TGFBR3 | Membranous nephropathy | Knockout or knock-in in podocytes |
| MAPK14 | Skin wound healing and myofibroblast differentiation | Knockout in dermal fibroblasts |
| IL1RL1 | Renal fibrosis | Knockout or overexpression in kidney tissue |
TGF-beta receptor activity in fibrosis
TGF-beta receptor signaling is a central driver of fibrosis across organs. In unilateral ureteral obstruction models, dual inhibition of TGFBR1 and MAP4K4 with TK-850 reduces renal fibrosis. In skin wound healing, TGF-beta receptor-mediated p38 MAPK signaling drives enhanced myofibroblast differentiation in mice lacking hyaluronan synthases 1 and 3. Crosstalk between IL1RL1 and TGF-beta receptor signaling further promotes renal fibrosis.
TGF-beta receptor activity in cancer
TGF-beta receptor activity has context-dependent roles in cancer. Signaling interplay between TGF-beta receptor and PI3K/AKT pathways influences tumor progression and metastasis. The pathway can suppress early tumor formation but promote invasion and metastasis in advanced disease. Targeting receptor kinase activity is therefore an active area of therapeutic research.
TGF-beta receptor activity in kidney disease
TGFBR3-associated membranous nephropathy highlights the clinical relevance of TGF-beta receptor components in the kidney. TGF-beta receptor signaling also contributes to renal fibrosis through SMAD and non-SMAD pathways. These findings support the receptor as a candidate target in kidney disease.
TGF-beta receptor activity in fibroblast homeostasis
TGF-beta receptor is one of the essential growth factor receptors for fibroblast homeostasis and activation, alongside FGFR and PDGFR. Its activity controls extracellular matrix production and myofibroblast conversion, making it a key node in tissue remodeling.
From transforming growth factor beta receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR1 abolish TGF-beta-induced SMAD phosphorylation? | TGFBR1 knockout cell line |
| Does a specific kinase-domain mutation disable receptor activity? | Point-mutation knock-in of catalytically dead TGFBR1 |
| How does a disease-associated variant affect signaling? | Knock-in of patient-derived TGFBR1 or TGFBR2 variant |
| Where is the receptor localized during signaling? | Tagged knock-in of TGFBR1 or TGFBR2 with fluorescent tag |
| Does overexpression of TGFBR3 modulate ligand presentation? | TGFBR3 overexpression cell model |
| Which genes are required for TGF-beta receptor activity? | CRISPR library screening with pathway readout |
How to Study the transforming growth factor beta receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-SMAD immunoblot | SMAD2/3 phosphorylation | Confirm receptor activation or inhibition |
| In vitro kinase assay | Serine/threonine phosphorylation of substrate | Test inhibitors like SB-431542 |
| Luciferase reporter assay | SMAD-dependent transcription | Compare wild-type and mutant receptors |
| Phosphoproteomics | Global phosphorylation changes | Map non-SMAD crosstalk |
| qPCR | Expression of TGF-beta target genes | Assess fibrosis markers like COL1A1 and ACTA2 |
| Immunofluorescence | Receptor localization and SMAD nuclear translocation | Visualize signaling in situ |
| CRISPR knockout screening | Gene requirements for receptor activity | Identify modifiers of TGF-beta signaling |
| Co-immunoprecipitation | Receptor complex formation | Study TGFBR1/TGFBR2/TGFBR3 interactions |
Phospho-SMAD immunoblotting
Phospho-SMAD2/3 immunoblotting measures the immediate catalytic output of TGF-beta receptor activity after ligand stimulation. It is widely used to confirm receptor activation or inhibition by compounds such as SB-431542.
Kinase activity assays
In vitro kinase assays using recombinant TGFBR1 and substrate peptides quantify ATP-dependent serine/threonine phosphorylation, directly reflecting GO:0005024. These assays are used to test inhibitors like SB-431542 and TK-850.
Transcriptional reporter assays
SMAD-responsive luciferase reporters measure downstream transcriptional activation following receptor stimulation. They are useful for comparing wild-type and mutant receptors in CRISPR models.
Proteomics and phosphoproteomics
Phosphoproteomics can identify global substrates and signaling nodes downstream of TGF-beta receptor activity, including non-SMAD branches such as p38 MAPK and PI3K/AKT. This approach helps map crosstalk in disease models.
How CRISPR Can Be Used to Study GO:0005024 transforming growth factor beta receptor activity
Knockout
CRISPR knockout of TGFBR1, TGFBR2, or TGFBR3 abolishes or reduces TGF-beta receptor activity, enabling loss-of-function studies in fibrosis, cancer, and kidney disease models. Knockout of downstream effectors such as SMAD2/3 helps separate canonical from non-canonical signaling.
Point Mutation
Point mutations in the kinase domain of TGFBR1 or TGFBR2 can create catalytically dead or constitutively active receptors, allowing precise structure-function analysis of GO:0005024. Such models are valuable for testing whether specific residues are required for substrate phosphorylation.
Knock-in
Knock-in of disease-associated variants or fluorescent tags at the endogenous TGFBR1 or TGFBR2 locus enables physiological expression and real-time tracking of receptor activity. This approach is particularly useful for studying TGFBR3-associated membranous nephropathy.
Overexpression
Overexpression of TGFBR1, TGFBR2, or TGFBR3 can amplify receptor signaling and is used to study ligand presentation, pathway crosstalk, and fibrosis-related gene expression. Overexpression models also help validate inhibitor specificity.
How EDITGENE Supports transforming growth factor beta receptor activity Research
Researchers studying transforming growth factor beta receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, disease progression, or therapeutic response. Precise genetic models are essential to move from correlation to mechanism.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AMHR2 Knockout HEK293 Cell Line | EDJ-KQ365 | Human | 269 | Details Get a Quote |
| BMPR2 Knockout HEK293 Cell Line | EDJ-KQ373 | Human | 659 | Details Get a Quote |
| LTBP1 Knockout HEK293 Cell Line | EDJ-KQ389 | Human | 4052 | Details Get a Quote |
| TGFBR1 Knockout HEK293 Cell Line | EDJ-KQ762 | Human | 7046 | Details Get a Quote |
| TGFBR3 Knockout HEK293 Cell Line | EDJ-KQ2915 | Human | 7049 | Details Get a Quote |
| LTBP4 Knockout HEK293 Cell Line | EDJ-KQ6235 | Human | 8425 | Details Get a Quote |
| TGFBR3L Knockout HEK293 Cell Line | EDJ-KQ14938 | Human | 100507588 | Details Get a Quote |
| TGFBR2 Knockout HEK293 Cell Line | EDC07591 | Human | 7048 | Details Get a Quote |
| ACVRL1 Knockout HEK293 Cell Line | EDJ-KQ17795 | Human | 94 | Details Get a Quote |
| LTBP1 Knockout HCT 116 Cell Line | EDJ-KQ17982 | Human | 4052 | Details Get a Quote |
| TGFBR3 Knockout A-549 Cell Line | EDJ-KQ24006 | Human | 7049 | Details Get a Quote |
| TGFBR3 Knockout HCT 116 Cell Line | EDJ-KQ24007 | Human | 7049 | Details Get a Quote |
| TGFBR3 Knockout HeLa Cell Line | EDJ-KQ24008 | Human | 7049 | Details Get a Quote |
| LTBP4 Knockout A-549 Cell Line | EDJ-KQ30081 | Human | 8425 | Details Get a Quote |
| LTBP4 Knockout HCT 116 Cell Line | EDJ-KQ30082 | Human | 8425 | Details Get a Quote |
Displaying Records 1 To 15 Of 36 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About transforming growth factor beta receptor activity
What is transforming growth factor beta receptor activity?
It is the molecular function defined by GO:0005024, in which a receptor binds TGF-beta and transmits a signal by phosphorylating protein serine and threonine residues using ATP.
What genes are involved in transforming growth factor beta receptor activity?
Key genes include TGFBR1, TGFBR2, TGFBR3, SMAD2, SMAD3, SMAD4, and pathway crosstalk genes such as MAPK14, PIK3CA, AKT1, and IL1RL1.
What is the GO ID for transforming growth factor beta receptor activity?
The GO ID is GO:0005024, under the molecular_function ontology.
How is TGF-beta receptor activity inhibited?
Small molecules such as SB-431542 inhibit ALK4, ALK5, and ALK7, while TK-850 dual-inhibits TGFBR1 and MAP4K4.
What diseases are linked to TGF-beta receptor activity?
It is linked to fibrosis, cancer, kidney diseases including membranous nephropathy, and wound healing disorders.
How do you measure TGF-beta receptor activity?
Common methods include phospho-SMAD immunoblotting, in vitro kinase assays, luciferase reporters, and phosphoproteomics.
What is the role of TGFBR3 in TGF-beta receptor activity?
TGFBR3 (betaglycan) is an accessory receptor that modulates ligand presentation and is associated with membranous nephropathy.
Can CRISPR be used to study TGF-beta receptor activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect receptor function and downstream signaling.
What pathways crosstalk with TGF-beta receptor activity?
p38 MAPK, PI3K/AKT, and interleukin-1 receptor-like 1 signaling are known crosstalk pathways.
Why is TGF-beta receptor activity important in fibrosis?
It drives myofibroblast differentiation and extracellular matrix production, and its inhibition reduces fibrosis in preclinical models.
Conclusion
GO:0005024 transforming growth factor beta receptor activity is a central molecular function that converts TGF-beta binding into serine/threonine phosphorylation and diverse cellular responses. Its dysregulation contributes to fibrosis, cancer, and kidney disease, making it a high-value target for mechanistic and therapeutic research. CRISPR-based models and integrated screening approaches provide powerful tools to dissect this activity and identify new intervention points.
References
- 1. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 2. Vander Ark A et al.. 2018. TGF-β receptors: In and beyond TGF-β signaling.. Cell Signal 52:112-120 PMID: 30184463
- 3. Caza TN et al.. 2021. Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.. Kidney360 2(8):1275-1286 PMID: 35369660
- 4. Palfrey HA et al.. 2025. Transforming growth factor β receptor 1 and mitogen-activated protein 4 kinase 4 dual inhibitor, TK-850, reduces renal fibrosis in unilateral ureteral-obstructed mice.. J Pharmacol Exp Ther 392(8):103644 PMID: 40706137
- 5. Wang Y et al.. 2022. Transforming Growth Factor-β Receptor-Mediated, p38 Mitogen-Activated Protein Kinase-Dependent Signaling Drives Enhanced Myofibroblast Differentiation during Skin Wound Healing in Mice Lacking Hyaluronan Synthases 1 and 3.. Am J Pathol 192(12):1683-1698 PMID: 36063901
- 6. Zhu X et al.. 2023. Crosstalk between Interleukin-1 Receptor-Like 1 and Transforming Growth Factor-β Receptor Signaling Promotes Renal Fibrosis.. Am J Pathol 193(8):1029-1045 PMID: 37236504
- 7. Cheng MF et al.. 2024. Essential growth factor receptors for fibroblast homeostasis and activation: Fibroblast Growth Factor Receptor (FGFR), Platelet Derived Growth Factor Receptor (PDGFR), and Transforming Growth Factor β Receptor (TGFβR).. F1000Res 13:120 PMID: 38988879
- 8. Zhang L et al.. 2013. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.. Trends Biochem Sci 38(12):612-20 PMID: 24239264
